CN114630667B - 用于治疗癌症的vs-6063与ch5126766的组合 - Google Patents

用于治疗癌症的vs-6063与ch5126766的组合 Download PDF

Info

Publication number
CN114630667B
CN114630667B CN202080063860.3A CN202080063860A CN114630667B CN 114630667 B CN114630667 B CN 114630667B CN 202080063860 A CN202080063860 A CN 202080063860A CN 114630667 B CN114630667 B CN 114630667B
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
cancer
administered
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080063860.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN114630667A (zh
Inventor
U.班纳吉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CANCER RESEARCH INSTITUTE
Original Assignee
CANCER RESEARCH INSTITUTE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CANCER RESEARCH INSTITUTE filed Critical CANCER RESEARCH INSTITUTE
Priority to CN202510521492.7A priority Critical patent/CN120678780A/zh
Publication of CN114630667A publication Critical patent/CN114630667A/zh
Application granted granted Critical
Publication of CN114630667B publication Critical patent/CN114630667B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080063860.3A 2019-09-13 2020-09-11 用于治疗癌症的vs-6063与ch5126766的组合 Active CN114630667B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510521492.7A CN120678780A (zh) 2019-09-13 2020-09-11 用于治疗癌症的vs-6063与ch5126766的组合

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2019/074565 WO2021047783A1 (en) 2019-09-13 2019-09-13 Vs-6063 in combination with ch5126766 for the treatment of cancer
EPPCT/EP2019/074565 2019-09-13
PCT/EP2020/075455 WO2021048339A1 (en) 2019-09-13 2020-09-11 Vs-6063 in combination with ch5126766 for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510521492.7A Division CN120678780A (zh) 2019-09-13 2020-09-11 用于治疗癌症的vs-6063与ch5126766的组合

Publications (2)

Publication Number Publication Date
CN114630667A CN114630667A (zh) 2022-06-14
CN114630667B true CN114630667B (zh) 2025-05-13

Family

ID=67988988

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080063860.3A Active CN114630667B (zh) 2019-09-13 2020-09-11 用于治疗癌症的vs-6063与ch5126766的组合
CN202510521492.7A Pending CN120678780A (zh) 2019-09-13 2020-09-11 用于治疗癌症的vs-6063与ch5126766的组合

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510521492.7A Pending CN120678780A (zh) 2019-09-13 2020-09-11 用于治疗癌症的vs-6063与ch5126766的组合

Country Status (11)

Country Link
US (4) US11517573B2 (https=)
EP (1) EP4028010B1 (https=)
JP (3) JP2022547358A (https=)
KR (1) KR102945599B1 (https=)
CN (2) CN114630667B (https=)
AU (1) AU2020344829A1 (https=)
BR (1) BR112022004699A2 (https=)
CA (1) CA3152805A1 (https=)
MX (1) MX2022003063A (https=)
TW (1) TWI857024B (https=)
WO (3) WO2021047783A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021047783A1 (en) * 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer
AU2020388848A1 (en) * 2019-11-18 2022-05-26 Inxmed (Nanjing) Co., Ltd. Use of FAK inhibitor in preparation of drug for treating tumors having NRAS mutation
JP7582694B2 (ja) 2020-01-10 2024-11-13 イミューニヤリング コーポレーション Ｍｅｋ阻害剤及びその治療的使用
MX2022009612A (es) 2020-02-05 2022-09-19 Inxmed Nanjing Co Ltd Combinacion de bi853520 con farmacos quimioterapeuticos.
AU2021307410A1 (en) * 2020-07-13 2023-02-09 Verastem, Inc. Combination therapy for treating abnormal cell growth
EP4376828A4 (en) * 2021-07-27 2025-06-18 Verastem, Inc. COMBINATION THERAPY FOR THE TREATMENT OF ABNORMAL CELL GROWTH
TW202313044A (zh) 2021-08-16 2023-04-01 大陸商應世生物科技（南京）有限公司 Ｉｎ１００１８與ｐｌｄ的聯用
IL312248A (en) * 2021-10-28 2024-06-01 Verastem Inc Combined treatment for abnormal cell proliferation
IL312469A (en) * 2021-11-02 2024-06-01 Verastem Inc Methods of treating abnormal cell growth
TW202329967A (zh) * 2022-01-21 2023-08-01 大陸商應世生物科技（南京）有限公司 治療腫瘤的藥物組合及用途
EP4469086A4 (en) * 2022-01-25 2026-01-21 Verastem Inc POLYTHERAPY FOR THE TREATMENT OF ABNORMAL CELL GROWTH
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
CN114917232A (zh) * 2022-06-27 2022-08-19 厦门骨本生物科技有限公司 Ch5126766在制备缓解或治疗动物骨关节炎的药物中的应用
CN115177622B (zh) * 2022-07-19 2024-09-17 中南大学湘雅二医院 多个化合物在制备治疗骨髓增殖性肿瘤的药物中的应用
WO2024037498A1 (zh) * 2022-08-15 2024-02-22 海创药业股份有限公司 一种治疗卵巢癌的联合用药物
TW202517624A (zh) * 2023-07-03 2025-05-01 美商醫療免疫工程公司 Mek免疫腫瘤抑制劑醫藥組合物
WO2025079712A1 (ja) * 2023-10-12 2025-04-17 中外製薬株式会社 ドライバー変異を有するがん患者における分子標的薬併用療法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106102744A (zh) * 2014-01-09 2016-11-09 维瑞斯特姆股份有限公司 用于治疗异常细胞生长的组合物和方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9920908D0 (en) 1999-09-03 1999-11-10 Indena Spa Chalcone coumarins
WO2007025090A2 (en) * 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
BRPI0810411B8 (pt) 2007-04-18 2021-05-25 Pfizer Prod Inc derivados de sulfonil amida para o tratamento de crescimento celular anormal, seu sos, bem como composição farmacêutica
US8569378B2 (en) 2007-07-20 2013-10-29 Toshiyuki Sakai p27 protein inducer
KR101489045B1 (ko) 2009-10-12 2015-02-02 에프. 호프만-라 로슈 아게 Ｐｉ3ｋ 억제자 및 ｍｅｋ 억제자의 조합
WO2012045194A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
AR084216A1 (es) 2010-12-09 2013-05-02 Sanofi Sa Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
US20130004481A1 (en) 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
US9133174B2 (en) 2011-09-05 2015-09-15 Chugai Seiyaku Kabushiki Kaisha Method for producing coumarin derivative
WO2013170066A1 (en) 2012-05-09 2013-11-14 H. Lee Moffitt Cancer Center & Research Institute, Inc. Peptides for the treatment of cancer
WO2013182668A1 (en) 2012-06-08 2013-12-12 F. Hoffmann-La Roche Ag Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
KR20150067323A (ko) 2012-10-12 2015-06-17 글락소스미스클라인 엘엘씨 조합물
ES2779975T3 (es) 2014-02-07 2020-08-21 Verastem Inc Métodos y composiciones para tratar el crecimiento celular anormal
JP2018519327A (ja) 2015-06-29 2018-07-19 ベラステム・インコーポレーテッドＶｅｒａｓｔｅｍ，Ｉｎｃ． 治療用組成物、組合せ物および使用の方法
CA3074690A1 (en) * 2017-09-07 2019-03-14 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
RU2760006C1 (ru) 2017-11-16 2021-11-22 Дзе Инститьют оф Кансер Рисерч: Ройал Кансер Хоспитал Производное кумарина для лечения или профилактики расстройства пролиферации клеток
WO2021047783A1 (en) * 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106102744A (zh) * 2014-01-09 2016-11-09 维瑞斯特姆股份有限公司 用于治疗异常细胞生长的组合物和方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors;Shimizu T, Fukuoka K, Takeda M, et al.;Cancer chemotherapy and pharmacology;摘要、结果部分 *
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors;Jones S F, Siu L L, Bendell J C, et al.;Investigational new drugs;摘要、结果部分 *
Phase 1/1b study of the FAK inhibitor defactinib (VS-6063) in combination with weekly paclitaxel for advanced ovarian cancer;Patel M R, Infante J R, Moore K N 等;《Journal of Clinical Oncology;第15卷;摘要 *
Wada M, Horinaka M, Yamazaki T,等. The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.《 PLoS One 》.2014,第30卷摘要、结果部分、fig1-5. *

Also Published As

Publication number Publication date
US11517573B2 (en) 2022-12-06
CA3152805A1 (en) 2021-03-18
JP2025072587A (ja) 2025-05-09
US20220031698A1 (en) 2022-02-03
TW202114677A (zh) 2021-04-16
JP2022172480A (ja) 2022-11-17
BR112022004699A2 (pt) 2022-06-14
TWI857024B (zh) 2024-10-01
CN114630667A (zh) 2022-06-14
AU2020344829A1 (en) 2022-03-03
KR102945599B1 (ko) 2026-03-30
JP7634351B2 (ja) 2025-02-21
MX2022003063A (es) 2022-06-14
US20240197731A1 (en) 2024-06-20
WO2021047798A1 (en) 2021-03-18
WO2021048339A1 (en) 2021-03-18
KR20220078606A (ko) 2022-06-10
US12280050B2 (en) 2025-04-22
JP2022547358A (ja) 2022-11-14
EP4028010A1 (en) 2022-07-20
WO2021047783A1 (en) 2021-03-18
EP4028010B1 (en) 2026-04-08
US20230277535A1 (en) 2023-09-07
US20260034128A1 (en) 2026-02-05
CN120678780A (zh) 2025-09-23

Similar Documents

Publication Publication Date Title
CN114630667B (zh) 用于治疗癌症的vs-6063与ch5126766的组合
US20230330088A1 (en) Combination therapy for treating abnormal cell growth
JP2022172480A5 (https=)
KR20230011908A (ko) 비정상적 세포 성장을 치료하기 위한 조합 요법
US20200147080A1 (en) Methods and compositions for treating abnormal cell growth
KR20240041978A (ko) 비정상적 세포 성장을 치료하기 위한 조합 요법
HK40075762A (en) Vs-6063 in combination with ch5126766 for the treatment of cancer
KR20260046532A (ko) 암 치료를 위한 ch5126766과 조합된 vs-6063

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40075762

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant